Glimepiride 1 Mg + Metformin 500 Mg + Voglibose 0.2 Mg (SR) Tablets – GLIMRIL MV1

Glimepiride 1mg + Metformin 500mg + Voglibose 0.2mg (SR) Tablet – one solution to manage type 2 diabetes mellitus.

GLIMRIL MV1: The Triple composition of Glimepiride 1mg + Metformin 500mg + Voglibose 0.2mg (SR) (Bilayered Tab) combines Glimepiride, Voglibose, and Metformin, each with distinct mechanisms to effectively control blood glucose levels in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, enhances insulin secretion from the pancreas. Voglibose, an alpha-glucosidase inhibitor, slows carbohydrate absorption in the intestines, specifically helping with postprandial glucose control. Metformin, a biguanide, improves insulin sensitivity, decreases hepatic glucose production, and enhances peripheral glucose uptake.

Recommended By Specialists:
General Physicians: It is preferred to treat the disease associated with managing Type 2 Diabetes Mellitus (T2DM), especially in primary care settings.
Diabetologists: It is preferred that the disease be treated for the diagnosis and treatment of diabetes mellitus.
Endocrinologists: It is preferred to treat the disease associated with hormone-related conditions, especially diabetes management.

Key Benefits of Glimepiride 1 Mg + Metformin 500 Mg + Voglibose 0.2 Mg (SR) Tablets – GLIMRIL MV1:
Triple Mechanism of Action: This combination targets three different pathways—pancreatic insulin release, carbohydrate absorption, and insulin sensitivity—for enhanced blood glucose control.
Comprehensive Glycemic Management: The combination addresses both fasting and postprandial blood glucose, with Voglibose specifically helping to control post-meal spikes.
Extended-Release Metformin: The ER formulation of Metformin provides sustained blood glucose control with reduced gastrointestinal side effects, allowing once-daily dosing and improved patient adherence.

INDICATIONS:
Type 2 diabetes mellitus
Postprandial hyperglycemia
Prevention of long-term complications